Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph early_phase_1
1
13%
Ph phase_4
4
50%
Ph phase_2
1
13%
Ph not_applicable
2
25%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 4Post-market surveillance
4(50.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 44 (50.0%)
N/A2 (25.0%)

Trials by Status

completed675%
unknown113%
terminated113%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
DRUG
Total Trials
8